{"id":59031,"date":"2024-03-13T04:06:43","date_gmt":"2024-03-13T03:06:43","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/cybin-to-host-conference-call-and-webcast-to-provide-program-update-for-cyb003\/"},"modified":"2024-03-13T04:06:43","modified_gmt":"2024-03-13T03:06:43","slug":"cybin-to-host-conference-call-and-webcast-to-provide-program-update-for-cyb003","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/cybin-to-host-conference-call-and-webcast-to-provide-program-update-for-cyb003\/","title":{"rendered":"Cybin to Host Conference Call and Webcast to Provide Program Update for CYB003"},"content":{"rendered":"
\n

\n\u00a0– Program update includes 4-month durability data from Phase 2 trial of CYB003 in Major Depressive Disorder (\u201cMDD\u201d) –<\/i><\/p>\n

\n– Company speakers include Doug Drysdale, Chief Executive Officer and Amir Inamdar, MBBS, DNB (Psych), MFPM, Chief Medical Officer –<\/i><\/p>\n

TORONTO–(BUSINESS WIRE)–Cybin Inc.<\/a> (NYSE American:CYBN) (Cboe CA:CYBN) (\u201cCybin<\/b>\u201d or the \u201cCompany<\/b>\u201d), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options, today announced that it will host a conference call and webcast at 8:30 a.m. ET on Wednesday, March 13, 2024.<\/p>\n

<\/a>
<\/a><\/p>\n

\nThe Company will provide a program update on CYB003, its proprietary deuterated psilocybin analog in development for the adjunctive treatment of MDD, including 4-month durability results from the Company\u2019s Phase 2 trial.<\/p>\n

\nConference Call and Webcast Details:<\/b><\/p>\n

\nDate: Wednesday, March 13, 2024<\/p>\n

\nTime: 8:30 a.m. ET.<\/p>\n

\nDial-in: 800-267-6316 (U.S. Toll-Free) or 203-518-9783 (International)<\/p>\n

\nConference ID: CYBN0313<\/p>\n

\nWebcast: Register for the webcast here<\/a><\/p>\n

\nThe archived webcast will also be available on the Company\u2019s investor relations website on the Events & Presentations<\/a> page.<\/p>\n

\nAbout Cybin<\/b><\/p>\n

\nCybin is a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions.<\/p>\n

\nCybin\u2019s goal of revolutionizing mental healthcare is supported by a network of world-class partners and internationally recognized scientists aimed at progressing proprietary drug discovery platforms, innovative drug delivery systems, and novel formulation approaches and treatment regimens. The Company is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds.<\/p>\n

\nHeadquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. For company updates and to learn more about Cybin, visit www.cybin.com<\/a> or follow the team on X, LinkedIn, YouTube and Instagram.<\/p>\n

Contacts<\/b> <\/p>\n

\nInvestor & Media:<\/b>
Gabriel Fahel
\n
Chief Legal Officer
\n
Cybin Inc.
\n
1-866-292-4601
\n
irteam@cybin.com<\/a> \u2013 or \u2013 media@cybin.com<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

\u00a0– Program update includes 4-month durability data from Phase 2 trial of CYB003 in Major Depressive Disorder (\u201cMDD\u201d) – – Company speakers include Doug Drysdale, Chief Executive Officer and Amir Inamdar, MBBS, DNB (Psych), MFPM, Chief Medical Officer – TORONTO–(BUSINESS WIRE)–Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (\u201cCybin\u201d or the \u201cCompany\u201d), a clinical-stage biopharmaceutical company committed … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-59031","6":"format-standard","7":"category-industry"},"yoast_head":"\nCybin to Host Conference Call and Webcast to Provide Program Update for CYB003 - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/cybin-to-host-conference-call-and-webcast-to-provide-program-update-for-cyb003\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cybin to Host Conference Call and Webcast to Provide Program Update for CYB003 - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"\u00a0– Program update includes 4-month durability data from Phase 2 trial of CYB003 in Major Depressive Disorder (\u201cMDD\u201d) – – Company speakers include Doug Drysdale, Chief Executive Officer and Amir Inamdar, MBBS, DNB (Psych), MFPM, Chief Medical Officer – TORONTO–(BUSINESS WIRE)–Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (\u201cCybin\u201d or the \u201cCompany\u201d), a clinical-stage biopharmaceutical company committed ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/cybin-to-host-conference-call-and-webcast-to-provide-program-update-for-cyb003\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2024-03-13T03:06:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20240311987587\/en\/1908939\/22\/Cybin_Side_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cybin-to-host-conference-call-and-webcast-to-provide-program-update-for-cyb003\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cybin-to-host-conference-call-and-webcast-to-provide-program-update-for-cyb003\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Cybin to Host Conference Call and Webcast to Provide Program Update for CYB003\",\"datePublished\":\"2024-03-13T03:06:43+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cybin-to-host-conference-call-and-webcast-to-provide-program-update-for-cyb003\\\/\"},\"wordCount\":363,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cybin-to-host-conference-call-and-webcast-to-provide-program-update-for-cyb003\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20240311987587\\\/en\\\/1908939\\\/22\\\/Cybin_Side_Logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cybin-to-host-conference-call-and-webcast-to-provide-program-update-for-cyb003\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cybin-to-host-conference-call-and-webcast-to-provide-program-update-for-cyb003\\\/\",\"name\":\"Cybin to Host Conference Call and Webcast to Provide Program Update for CYB003 - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cybin-to-host-conference-call-and-webcast-to-provide-program-update-for-cyb003\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cybin-to-host-conference-call-and-webcast-to-provide-program-update-for-cyb003\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20240311987587\\\/en\\\/1908939\\\/22\\\/Cybin_Side_Logo.jpg\",\"datePublished\":\"2024-03-13T03:06:43+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cybin-to-host-conference-call-and-webcast-to-provide-program-update-for-cyb003\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cybin-to-host-conference-call-and-webcast-to-provide-program-update-for-cyb003\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cybin-to-host-conference-call-and-webcast-to-provide-program-update-for-cyb003\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20240311987587\\\/en\\\/1908939\\\/22\\\/Cybin_Side_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20240311987587\\\/en\\\/1908939\\\/22\\\/Cybin_Side_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cybin-to-host-conference-call-and-webcast-to-provide-program-update-for-cyb003\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cybin to Host Conference Call and Webcast to Provide Program Update for CYB003\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cybin to Host Conference Call and Webcast to Provide Program Update for CYB003 - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/cybin-to-host-conference-call-and-webcast-to-provide-program-update-for-cyb003\/","og_locale":"en_US","og_type":"article","og_title":"Cybin to Host Conference Call and Webcast to Provide Program Update for CYB003 - Pharma Trend","og_description":"\u00a0– Program update includes 4-month durability data from Phase 2 trial of CYB003 in Major Depressive Disorder (\u201cMDD\u201d) – – Company speakers include Doug Drysdale, Chief Executive Officer and Amir Inamdar, MBBS, DNB (Psych), MFPM, Chief Medical Officer – TORONTO–(BUSINESS WIRE)–Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (\u201cCybin\u201d or the \u201cCompany\u201d), a clinical-stage biopharmaceutical company committed ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/cybin-to-host-conference-call-and-webcast-to-provide-program-update-for-cyb003\/","og_site_name":"Pharma Trend","article_published_time":"2024-03-13T03:06:43+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20240311987587\/en\/1908939\/22\/Cybin_Side_Logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/cybin-to-host-conference-call-and-webcast-to-provide-program-update-for-cyb003\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/cybin-to-host-conference-call-and-webcast-to-provide-program-update-for-cyb003\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Cybin to Host Conference Call and Webcast to Provide Program Update for CYB003","datePublished":"2024-03-13T03:06:43+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/cybin-to-host-conference-call-and-webcast-to-provide-program-update-for-cyb003\/"},"wordCount":363,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/cybin-to-host-conference-call-and-webcast-to-provide-program-update-for-cyb003\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20240311987587\/en\/1908939\/22\/Cybin_Side_Logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/cybin-to-host-conference-call-and-webcast-to-provide-program-update-for-cyb003\/","url":"https:\/\/pharma-trend.com\/en\/cybin-to-host-conference-call-and-webcast-to-provide-program-update-for-cyb003\/","name":"Cybin to Host Conference Call and Webcast to Provide Program Update for CYB003 - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/cybin-to-host-conference-call-and-webcast-to-provide-program-update-for-cyb003\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/cybin-to-host-conference-call-and-webcast-to-provide-program-update-for-cyb003\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20240311987587\/en\/1908939\/22\/Cybin_Side_Logo.jpg","datePublished":"2024-03-13T03:06:43+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/cybin-to-host-conference-call-and-webcast-to-provide-program-update-for-cyb003\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/cybin-to-host-conference-call-and-webcast-to-provide-program-update-for-cyb003\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/cybin-to-host-conference-call-and-webcast-to-provide-program-update-for-cyb003\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20240311987587\/en\/1908939\/22\/Cybin_Side_Logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20240311987587\/en\/1908939\/22\/Cybin_Side_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/cybin-to-host-conference-call-and-webcast-to-provide-program-update-for-cyb003\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Cybin to Host Conference Call and Webcast to Provide Program Update for CYB003"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/59031","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=59031"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/59031\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=59031"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=59031"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=59031"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}